The ORF3b protein of severe acute respiratory syndrome coronavirus (SARS-CoV) has a nuclear localization signal (NLS) at its C terminus and antagonizes interferon (IFN) function by modulating the activity of IFN regulatory factor 3 (IRF3). SARS-like coronaviruses (SL-CoVs) found in bats share an identical genome organization and high sequence identity for most of their gene products. In this study, ORF3b homologues were identified from three bat SL-CoV strains. These ORF3b homologues were C-terminally truncated and lacked the C-terminal NLS of SARS-CoV. IFN antagonist activities analysis demonstrated that one SL-CoV ORF3b still possessed IFN antagonist and IRF3-modulating activities. These results indicate that different ORF3b proteins display different IFN antagonist activities and this function is independent of the protein's nuclear localization, suggesting a potential link between bat SL-CoV ORF3b function and viral pathogenesis.
INTRODUCTION
The interferon (IFN) system functions as the first line of defence against viral infection in mammalian cells. Viral infection triggers a variety of cellular sensors that, in turn, activate a series of molecules, ultimately leading to the production of type I IFN (IFN-a and -b) (García-Sastre & Biron, 2006) . One of these molecules, IFN regulatory factor 3 (IRF3), is essential for activation of the IFN-b gene promoter (Hiscott et al., 1999; Randall & Goodbourn, 2008) . IRF3 is expressed constitutively and localizes to the cytoplasm of uninfected cells. Upon activation by phosphorylation of its C-terminal domain mediated by TANKbinding kinase 1 (TBK1) and IkB kinase epsilon (IKKe) (Fitzgerald et al., 2003) , IRF3 translocates to the nucleus and promotes transcriptional activation. This activation leads to the production of IFN and several downstream antiviral genes, helping to establish an antiviral state.
To counteract the antiviral effects of IFN, viruses encode proteins to inhibit specific steps in IFN signalling or production (Basler et al., 2003; Kochs et al., 2007; Shaw et al., 2004) . Severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2003 and caused widespread mortality in humans, encodes at least five proteins that function as IFN antagonists (Devaraj et al., 2007; Kamitani et al., 2006; Kopecky-Bromberg et al., 2007) , suppressing components of both signalling and production.
These proteins are believed to be responsible for the pathogenesis of SARS-CoV. Several strains of SARS-like coronavirus (SL-CoV) have been identified in horseshoe bats and found to be closely related to the human SARS-CoVs. SL-CoVs are believed to be members of a highly diverse coronavirus population in bats that includes the immediate ancestor of SARS-CoV (Lau et al., 2005; Li et al., 2005; Ren et al., 2006) . Bat SL-CoVs and human SARS-CoV share an identical genome organization and high sequence identity for most of their gene products. However, a synthesized recombinant SL-CoV caused no clinical disease in mice compared with SARS-CoV (Becker et al., 2008) , indicating a difference in pathogenesis between the two viruses, at least in mice. SARS-CoV mRNA 3 encodes ORF3a and ORF3b proteins, both of which can be detected in SARS-CoV-infected tissues . ORF3b shares a large part of its coding sequence with ORF3a with the exception of the C-terminal end (aa 134-154), which contains a nuclear localization signal (NLS). Despite the sequence similarity, ORF3a and ORF3b are translated in different reading frames and encode distinct proteins. SARS-CoV ORF3b, which encodes a 154 aa protein, has been shown to be an IFN antagonist (Kopecky-Bromberg et al., 2007) . ORF3b homologues have been identified for bat SL-CoV strains Rf1, Rm1 and Rp3 (Li et al., 2005) , but the three genes have different C-terminal truncations (Fig. 1 ). In this study, we analysed the cellular localization and IFN antagonism of these ORF3b proteins and compared the results with those for SARS-CoV ORF3b.
RESULTS

Bat SL-CoV ORF3b homologues display different C-terminal truncations and different cellular locations
The ORF3b proteins from bat SL-CoV strains Rf1 (Rf3b), Rm1 (Rm3b) and Rp3 (Rp3b) were 114, 56 and 56 aa and shared amino acid sequence identities of 91, 62 and 64 %, respectively, with the ORF3b of SARS-CoV Urbani (Ur3b). The size differences were the result of a TAA stop codon in the SL-CoV ORF3b genes, leading to premature translation termination ( Fig. 1 ).
For functional analyses, the ORF3b genes were cloned into a pCAGGS vector, which contains an N-terminal HA tag (Kochs et al., 2007) . Successful expression and cellular localization were analysed by Western blotting and confocal microscopy using an anti-HA antibody (Beyotime) (Fig. 2) . For all the ORF3b constructs, the expressed proteins displayed a doublet in the Western blot ( Fig. 2a ), which was predicted to be the result of posttranslational modification, although we are not sure which form of modification was responsible. However, we did detect a number of phosphorylation sites in the ORF3b sequences. To avoid cell toxicity caused by the overexpression of some gene constructs, a relatively short period of expression (16 h) was adopted, followed by immediate analysis after cell permeabilization. Unlike Ur3b, which was observed in the nucleus (Fig. 2b) , all three SL-CoV ORF3b proteins (Rf3b, Rm3b and Rp3b) were found only in the cytoplasm (Fig. 2b) . A putative NLS has been identified between aa 134 and 154 of Ur3b 
Bat SL-CoV ORF3b homologues display different IFN antagonist activities
To investigate whether the SL-CoV ORF3b proteins are IFN antagonists despite their non-nuclear localization, we measured IFN-b promoter activation in response to Sendai virus (SeV) infection in the presence or absence of the ORF3b proteins. Human 293T cells were co-transfected with p125Luc (containing the IFN-b promoter fused to the firefly luciferase gene in a pGL3 vector), internal control plasmid pRL-TK (constitutively expressing Renilla luciferase) and a plasmid containing one of the following: ORF3b, influenza virus strain PR8 NS1 (positive control) (Kochs et al., 2007) or no insert (empty negative-control vector). At 24 h post-transfection (p.t.), the cells were infected with SeV. At 18 h post-infection (p.i.), samples were analysed with a Dual-Luciferase Reporter Assay System (Promega). An aliquot of lysate was also examined for expression of ORF3b, and a pattern similar to those in Fig. 2 (a) was observed (data not shown). Expression of the Rf3b gene resulted in severe cytotoxicity, preventing further analysis in this study.
Measurements of IFN-b activation inhibition are shown in Fig. 3(a) . As expected, the positive control (NS1) demonstrated the strongest inhibition (almost 100 %), whilst Ur3b exhibited~60 % inhibition. Interestingly, whilst Rp3b showed no inhibition at all, Rm3b demonstrated an inhibition equal to or better than that of Ur3b. The reduced luciferase activity was not a result of decreased cell viability among samples, shown by a comparison of cell morphology and production of Renilla luciferase, which served as an internal control. This observation was confirmed at the mRNA level by RT-PCR analysis (Fig. 3b ). 
Rm3b inhibits activation of IRF3 differently from Ur3b
IRF3 is activated by phosphorylation of its C-terminal domain by TBK-1 and IKKe (Fitzgerald et al., 2003) , which allows it to be transported into the nucleus. As overexpression of either TBK-1 or IKKe had no effect on the inhibition profile of Ur3b or Rm3b (data not shown), we shifted our focus to IRF3. Cells were co-transfected with plasmids expressing IRF3, p125Luc, pRL-TK and either ORF3b or a control vector. At 24 h p.t., the cells were infected with SeV. After 18 h incubation, dual-luciferase activity was determined. An inhibition pattern was observed for constructs Rm3b, Ur3b and NS1, with NS1 showing the greatest inhibition, followed by Rm3b and Ur3b (Fig. 4a ). We then examined the inhibition profile in the presence of IRF3(5D), a constitutively active mutant of IRF3 (Chang et al., 2006) . A similar inhibition profile was observed to that described above (Fig. 4b) . In all cases, expression of the expected IRF3 and IRF3(5D) proteins was confirmed by Western blotting (data not shown). Taken together, these data suggested that, like Ur3b, Rm3b could inhibit IRF3-dependent IFN gene expression.
Ur3b is known to block the translocation of activated IRF3 from the cytoplasm to the nucleus (Kopecky-Bromberg et al., 2007) . To investigate whether Rm3b had the same function, the subcellular distribution of IRF3 was determined in the presence and absence of ORF3b proteins. HeLa cells were transfected with plasmids expressing NS1, Ur3b or Rm3b and incubated for 24 h, followed by SeV infection. After 8 h incubation, IRF3 distribution was determined by confocal immunofluorescence microscopy using a primary rabbit anti-IRF3 polyclonal antibody (Proteintech Group) and an FITC-conjugated goat antirabbit secondary antibody (Pierce). As shown in Fig. 4(c) , IRF3 was localized to the cytoplasm of mock-infected cells. Upon SeV infection, the majority of IRF3 was translocated to the nucleus (90 %). This translocation was blocked to various degrees when NS1, Ur3b or Rm3b was coexpressed. An inhibition effect of 95, 88 and 96 % was determined, respectively, by counting labelled IRF3. To demonstrate further the effect of ORF3b in blocking IRF3 translocation, co-labelling of ORF3b and IRF3 was conducted. As shown in Fig. 4(d) , whilst almost all Rm3b-expressing cells had IRF3 in the cytoplasm, some Ur3b-expressing cells had IRF3 in the nucleus, further indicating that Rm3b is more effective than Ur3b in blocking IRF3 translocation upon activation by viral (SeV) infection.
DISCUSSION
In this study, we showed that the ORF3b proteins of SARS-CoV and SL-CoV share substantial sequence identity and are co-linear at the N terminus, which is unique to ORF3b but not to ORF3a. Alignment of ORF3b proteins from different SARS-CoVs with bat SL-CoVs demonstrated that ORF3b was conserved at the N-terminal end among different SARS-CoVs, suggesting that they do encode virus proteins. However, the SL-CoV ORF3b proteins were smaller in size than SARS-CoV ORF3b due to truncations at the C termini from in-frame stop codons, and all three were cytoplasmic due to the lack of an NLS at the C terminus. Whilst mutations in Rp3, Rm1 and Rf1 caused early translation termination, they had minimal impact on the protein sequences of ORF3a (no change in the case of Rf1, 1 aa change in Rp3 and Rm1). Although the NLScontaining C-terminal end (aa 134-154) is the only ORF3b-specific region, it may not be important to its function as an IFN-b antagonist, as described previously (Freundt et al., 2009) and observed in the present study. Furthermore, this C-terminal truncation in ORF3 also exists in other CoVs, such as infectious bronchitis virus, indicating that the CoV ORF3 is functionally tricistronic (Liu & Inglis, 1992; Liu et al., 1991) .
Interestingly, the three SL-CoV ORF3b proteins displayed very different activities with regard to IFN suppression. The largest SL-CoV ORF3b protein, Rf3b, was toxic to cells after incubation for 18 h or longer but did not induce cell apoptosis (data not shown). Of the two smaller SL-CoV ORF3b proteins, Rp3b showed no IFN antagonism, whereas Rm3b was a potent IFN antagonist that was even more active than Ur3b, the SARS-CoV ORF3b. Furthermore, we provided data to show that both Ur3b and Rm3b employ the same mechanism of IFN-b inhibition, blocking IRF3 translocation into the nucleus and thus preventing activation of the IFN-b gene promoter.
As a highly pathogenic virus, SARS-CoV encodes at least five proteins acting as IFN antagonists, including ORF3b, ORF6, nucleocapsid protein (Kopecky-Bromberg et al., 2007) and a number of products of ORF1 (Devaraj et al., 2007; Frieman et al., 2009; Kamitani et al., 2006) . These proteins suppress IFN production or signalling through different mechanisms. With the exception of ORF3b, the bat SL-CoV homologues of these genes share high sequence identities with their SARS-CoV counterparts (Li et al., 2005; Ren et al., 2006) . As attempts to isolate live SL-CoV have been uniformly unsuccessful to date, it is not possible to determine whether the different IFN-b antagonist activities of SL-CoV ORF3b observed in this study can be correlated with the pathogenicities of these viruses. In this regard, it is interesting to note that a recombinant SL-CoV virus (Bat-SRBD-MA) containing a truncated 39 aa ORF3b protein was non-pathogenic in aged mice (Becker et al., 2008) . Based on the results of our present study, we predict that this truncated ORF3b is unlikely to function as an IFN antagonist. It will be interesting to determine whether insertion of a functional ORF3b into Bat-SRBD-MA will have any effect on the pathogenicity of this recombinant virus.
Additionally, the NSP1 protein of SL-CoV Rm1 was shown recently to be a functional IFN antagonist (Tohya et al., 2009) . Taken together with our data, it can be concluded that both SL-CoV Rm1 and SARS-CoV share at least two homologous proteins that can function as IFN antagonists.
Considering the much smaller size of Rm3b compared with Ur3b and their different subcellular locations, we were surprised to find that Rm3b was more active than Ur3b as an IFN-b antagonist. Our study demonstrated that a Cterminal NLS is not required for an ORF3b protein to function as an IFN-b antagonist. This conclusion is supported by a recent report showing that the nuclear localization of Ur3b is not static; rather, the protein is shuttled between the nucleus and cytoplasm (Freundt et al., 2009) , which was also evident in our current study. At 32 h p.t., we observed substantial Ur3b in the cytoplasm (Fig. 4d) . However, at 16 h p.t., the majority of Ur3b was nuclear (Fig. 2b) . It seems reasonable to suggest that the main site of action for IFN antagonism by ORF3b is in the cytoplasm. Consequently, the biological significance of the NLS in Ur3b remains elusive at the present time. Our attempt to delete the NLS region in Ur3b, thus creating a molecule with the same size as Rf3b (114 aa), was unsuccessful because it was toxic to the cell system used in this study (as was Rf3b).
Finally, it should be noted that the IFN detection system used in this study was derived from and performed in human cells. Thus, it will be interesting to conduct the same studies in bat cells to determine whether these ORF3b homologues will have the same IFN antagonism profiles as those observed in the human cell system. The development of different Rhinolophus bat cell lines (Z. S., unpublished results; Crameri et al., 2009) , which is the reservoir host of SL-CoV, will facilitate this research in future. Bat SL-CoV ORF3b antagonizes IFN METHODS Cells and virus. 293T and HeLa cells were cultured in Dulbecco's modified Eagle's medium (Gibco) containing 10 % FBS. SeV strain Cantell was grown in 10-day-old embryonated chicken eggs at 37 uC for 48 h.
Plasmids. Bat SL-CoV ORF3b genes (Rf1, Rm1 and Rp3) were amplified by PCR from SL-CoV plasmids constructed previously (Li et al., 2005) . ORF3b of SARS-CoV was obtained from a SARS-CoV infectious cDNA clone. All the ORF3b genes were cloned into the pCAGGS vector constructed with an N-terminal HA tag. A positive control, plasmid pCAGGS-HA-NS1(PR8) encoding the NS1 protein of influenza strain PR8, was kindly provided by Dr Georg Kochs (Department of Virology, University of Freiburg, Germany). Successful expression of the proteins was confirmed by Western blotting using a mAb against the HA tag (Beyotime).
The plasmid p125Luc was constructed by inserting the IFN-b promoter (positions 2125 to +19) fused to the firefly luciferase gene in the pGL3 basic vector (Promega). The IRF3 and IRF3(5D) expression plasmids, pIRES-hrGFP/IRF3-Flag and pIRES-hrGFP/IRF3(5D)-Flag, were kindly provided by Professor Y. L. Lin (National Defense Medical Center, Taiwan, PR China).
Transfection and reporter gene assays. 293T cells were transfected using a calcium phosphate method (Mammalian Transfection kit; Promega) according to the manufacturer's instructions. Approximately 5610 5 cells per well were co-transfected with 0.5 mg p125Luc, 0.1 mg of the constitutive Renilla luciferase construct pRL-TK (Promega), which served as an internal control, and 2.5 mg relevant expression plasmid. Where indicated, expression plasmids for IRF3(5D) (50 ng) and IRF3(50 ng) were included in the transfection mix. Cells were harvested at 24 h p.t. and lysed. Luciferase activity was determined using a dual-luciferase assay system (Promega) in a Turner Designs TD-20/20 luminometer.
Indirect immunofluorescence assay and confocal microscopy.
HeLa cells were seeded onto glass coverslips in a 24-well plate and transfected with 0.8 mg HA-tagged ORF3b expression plasmids per well using Fugene HD regent (Roche). At 24 h p.t., cells were treated with 100 SeV HA units per well and fixed for 10 min at room temperature with 4 % paraformaldehyde at 8 h p.i. After three washes with PBS/0.1 % Tween 20, the cells were incubated with blocking buffer (PBS/3 % BSA) for 30 min and then with primary antibody, mouse mAb against the HA tag (Beyotime) and rabbit anti-IRF3 polyclonal antibody (Proteintech Group), for 1 h at 37 uC. Cells were washed three times and then incubated with FITC-conjugated goat anti-rabbit and TRITC-conjugated goat anti-mouse (Pierce) antibodies at a dilution of 1 : 100 for 30 min at 37 uC. After a further three washes, the slides were mounted with 50 % glycerol and observed under a Leica confocal microscope. For analysis of the localization of ORF3b, the immunofluorescence assay was carried out following the same procedure using mouse mAb against the HA tag and FITC-conjugated goat anti-mouse antibody (Pierce). Cells were then nuclear stained with Hoechst 33258 (Beyotime) for 5 min at room temperature. After washing, the cells were mounted with 50 % glycerol and observed under a Leica confocal microscope.
